Blueprint
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
report (Date of earliest event reported): November 10, 2016
|
CORMEDIX
INC.
|
|
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
|
|
Delaware
|
001-34673
|
20-5894890
|
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
|
|
|
|
1430
U.S. Highway 206, Suite 200, Bedminster NJ
|
07921
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code: (908) 517-9500
|
|
|
(Former
Name or Former Address, If Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 2.02.
Results of Operations and Financial Condition.
On November 10, 2016, CorMedix, Inc. issued
a press release announcing its operating results for the third
quarter ended September 30, 2016. A
copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein in its entirety by
reference.
The
information in this Item 2.02 (including Exhibit 99.1) shall
not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act, except
as expressly set forth by specific reference in such a
filing.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press release dated
November 10, 2016.
|
|
|
|
|
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
CORMEDIX
INC.
|
|
|
|
|
|
|
Date:
November 10,
2016
|
By:
|
/s/
Khoso
Baluch
|
|
|
|
Name: |
Khoso
Baluch |
|
|
|
Title: |
Chief Executive
Officer
|
|